I. Alex Bowman, MD

home / authors / i-alex-bowman-md

I. Alex Bowman, MD is a Genitourinary Medical Oncologist at the Banner Gateway Medical Center in Gilbert, AZ.

Articles

Dr Bowman on the Role of Kidney Cancer Awareness in Earlier Detection and Improved Patient Outcomes

Dr Bowman on Risk Factors for Kidney Cancer Development

I. Alex Bowman, MD
April 21st 2025

I. Alex Bowman, MD, discusses recommended strategies for kidney cancer risk reduction.

Read More

Dr Bowman on the Safety of TKI and Immunotherapy Combinations in Non–Clear Cell RCC

Dr Bowman on the Safety of TKI and Immunotherapy Combinations in Non–Clear Cell RCC

I. Alex Bowman, MD
March 31st 2025

Dr Bowman discusses immune-related and TKI-specific toxicities when combining immunotherapy and TKIs in non–clear cell RCC.

Read More

Dr Bowman on the Role of Kidney Cancer Awareness in Earlier Detection and Improved Patient Outcomes

Dr Bowman on the Role of Kidney Cancer Awareness in Earlier Detection and Improved Patient Outcomes

I. Alex Bowman, MD
March 27th 2025

Alex Bowman, MD, discusses the need for early symptom recognition, genetic risk evaluation, and research support to improve RCC detection and outcomes.

Read More

Dr. Bowman on Rationale for Radio-Labeled Atezolizumab PET/CT Scans in RCC

Dr. Bowman on Rationale for Radio-Labeled Atezolizumab PET/CT Scans in RCC

I. Alex Bowman, MD
December 10th 2019

I. Alex Bowman, MD, discusses the rationale for an exploratory clinical trial of radio-labeled 89Zr-atezolizumab PET/CT scans in renal cell carcinoma.

Read More

Latest Updated Articles

Arielle Heeke, MD
Published: May 2nd 2025 | Updated: May 6th 2025
Adjuvant CDK4/6 Inhibition Gains Further Ground in HR+/HER2– Early Breast Cancer With Ribociclib Approval
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Published: March 10th 2025 | Updated: April 25th 2025
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Núria Agustí Garcia, MD
Published: April 21st 2025 | Updated: April 23rd 2025
Dr Agustí on Patient Eligibility for Evaluating Chemoradiotherapy vs Radiotherapy Alone in Intermediate-Risk Cervical Cancer
Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Published: April 16th 2025 | Updated: April 18th 2025
Prognostic and Predictive Role of Circulating Tumor DNA (ctDNA) in Stage III Colon Cancer Treated With Celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer
Published: February 18th 2025 | Updated: April 17th 2025
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
Published: December 17th 2024 | Updated: March 26th 2025
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer